naxagolide has been researched along with oxidopamine in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hutson, PH; Suman-Chauhan, N | 1 |
Clineschmidt, BV; Jones, JH; Martin, GE; Pettibone, DJ; Williams, M; Yarbrough, GG | 1 |
Bankiewicz, KS; Belluzzi, JD; Domino, EF; May, JM; McAfee, DA | 1 |
3 other study(ies) available for naxagolide and oxidopamine
Article | Year |
---|---|
Activation of postsynaptic striatal dopamine receptors, monitored by efflux of cAMP in vivo.
Topics: Animals; Benzazepines; Colforsin; Corpus Striatum; Cyclic AMP; Desipramine; Dopamine Agents; Hydroxydopamines; Kinetics; Male; Oxazines; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Sulpiride; Synapses | 1990 |
Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].
Topics: Adenylyl Cyclases; Animals; Apomorphine; Binding, Competitive; Body Temperature; Brain Stem; Female; Fishes; Humans; Hydroxydopamines; Mice; Motor Activity; Oxazines; Oxidopamine; Posture; Rats; Rats, Inbred Strains; Receptors, Dopamine; Retina; Spiperone; Stereotyped Behavior; Vomiting | 1984 |
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Dominance, Cerebral; Dopamine Agents; Female; Injections, Intramuscular; Macaca nemestrina; Male; Oxazines; Oxidopamine; Parkinson Disease, Secondary; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes | 1994 |